Intercell AG

EANS-News: Intercell completed the acquisition of Cytos' antibody technology platform

-------------------------------------------------------------------------------- Corporate news transmitted by euro adhoc. The issuer/originator is solely responsible for the content of this announcement. -------------------------------------------------------------------------------- Strategic management decisions Vienna (Austria), June 8, 2010 (euro adhoc) - Intercell AG (VSE: ICLL) today announced the closing of the acquisition of Cytos' platform technology for monoclonal antibody discovery. On May 6, 2010 Intercell had announced the intent to acquire that technology, which is based on expression cloning of monoclonal antibodies from human B-cells, for EUR 15m. The antibody technology complements Intercell's technology platforms and opens novel medically and commercially relevant applications for Intercell's Antigen Identification Program (AIP®). end of announcement euro adhoc -------------------------------------------------------------------------------- ots Originaltext: Intercell AG Im Internet recherchierbar: http://www.presseportal.ch Further inquiry note: Intercell AG Lucia Malfent Vice President, Global Head Corporate Communications Tel. +43 1 20620-1303 lmalfent@intercell.com Branche: Biotechnology ISIN: AT0000612601 WKN: A0D8HW Index: ATX Prime, ATX Börsen: Wien / official market

Das könnte Sie auch interessieren: